<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Press Releases

Jump to a page: News Media Kit

Biodesix Receives CareFirst BlueCross BlueShield (BCBS) Coverage for VeriStrat Test

Biodesix' VeriStrat test has won approval from CareFirst BlueCross BlueShield

Lung Cancer Journal: VeriStrat Proteomic Test Improves Overall Survival and Decreases Medical Costs for Patients with Advanced NSCLC

The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.

Biodesix And Inivata To Investigate Clinical Utility Of Next Generation Sequencing-Blood Based Tests For Patients With Advanced Lung Cancer

Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.

Biodesix Raises Additional Series E Financing

In addition to the $15 million of series shares in 2013 and 2014, Biodesix brought in another $12 million, for total proceeds of $27 million from the sale.

Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines

VeriStrat blood-based prognostic and predictive proteomics test has been approved for in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).

AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress

Results from an exploratory analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.

Biodesix Receives Highmark Blue Cross Blue Shield Coverage for VeriStrat Test

Biodesix' Veristrat test is now covered by Highmark BCBS.

Biodesix Announces Publication of Seminal PROSE Study in THE LANCET ONCOLOGY

Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)

AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC

AVEO and Biodesix announce a groundbreaking partnership on ficlatuzumab

Biodesix Receives CE Mark for VeriStrat Specimen Collection and Shipping Kit

CE Mark clears Biodesix to make VeriStrat results available to physicians in the European Union and other countries recognizing the CE Mark.